GlassScriptPhysician profile
Joseph E Ambrose
NPI 1467451476
$2,674.86
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $1,211.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $387.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $349.88 | 2019-2020 | |
| Lilly USA, LLC | $348.67 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $258.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $252.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $194.18 | 2019-2020 | |
| Pfizer INC. | $163.02 | 2019-2020 | |
| Astellas Pharma US INC | $117.80 | 2019-2020 | |
| Amgen INC. | $87.33 | 2019-2020 | |
| Alfasigma USA, INC. | $60.65 | 2020 | |
| Allergan, INC. | $46.70 | 2020 | |
| Glaxosmithkline, LLC. | $43.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $41.93 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.44 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.48 | 2019 | |
| Collegium Pharmaceutical, INC. | $20.13 | 2020 | |
| Celgene Corporation | $15.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ambrose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.